Table 3.
Incidence of Supine SBP >160, >180, and >200 mmHg by Double-Blind Treatment
| Pooled Studies NOH301 and NOH302 | Study NOH306 | |||||||
|---|---|---|---|---|---|---|---|---|
| Variable | Droxidopa (n = 131) |
Placebo (n = 132) |
Droxidopa (n = 114) |
Placebo (n = 108) |
||||
| Baselinea | End of Study | Baselineb | End of Study | Baseline | Overall | Baseline | Overall | |
| Duration of exposure, wk | 1–2 | 8–10 | ||||||
| Observed supine SBP,c n (%) | ||||||||
| > 160 mmHg | 5 (3.8) | 13 (9.9) | 3 (2.3) | 8 (6.1) | 5 (4.4) | 33 (28.9) | 9 (8.3) | 26 (24.1) |
| > 180 mmHg | 0 | 4 (3.1) | 0 | 2 (1.5) | 0 | 9 (7.9) | 2 (1.9) | 5 (4.6) |
| > 200 mmHg | 0 | 0 | 0 | 0 | 0 | 4 (3.5) | 0 | 1 (0.9) |
SBP systolic blood pressure
a n = 130
b n = 131
cAt all 3 measurements during the 10-min supine period of an orthostatic standing test